Additionally, in triple-negative breast cancer, a micropeptide named ASRPS has been identified and shown to regulate the STAT3/VEGF signalling pathway, bind directly to STAT3, inhibits STAT3 phosphorylation, and reduce VEGF expression, thereby inhibiting tumour angiogenesis [58]. This evidence concerns the gene STAT3 and triple-negative breast carcinoma.